Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Cash & Equivalents: 2019-2025

Historic Cash & Equivalents for Harmony Biosciences Holdings (HRMY) over the last 5 years, with Sep 2025 value amounting to $647.0 million.

  • Harmony Biosciences Holdings' Cash & Equivalents rose 56.39% to $647.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $647.0 million, marking a year-over-year increase of 56.39%. This contributed to the annual value of $453.0 million for FY2024, which is 26.35% up from last year.
  • Harmony Biosciences Holdings' Cash & Equivalents amounted to $647.0 million in Q3 2025, which was up 18.49% from $546.0 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Cash & Equivalents registered a high of $647.0 million during Q3 2025, and its lowest value of $141.2 million during Q1 2021.
  • Moreover, its 3-year median value for Cash & Equivalents was $387.8 million (2024), whereas its average is $422.0 million.
  • Per our database at Business Quant, Harmony Biosciences Holdings' Cash & Equivalents dropped by 14.45% in 2021 and then skyrocketed by 59.03% in 2022.
  • Quarterly analysis of 5 years shows Harmony Biosciences Holdings' Cash & Equivalents stood at $234.3 million in 2021, then climbed by 22.43% to $286.9 million in 2022, then increased by 24.98% to $358.5 million in 2023, then climbed by 26.35% to $453.0 million in 2024, then soared by 56.39% to $647.0 million in 2025.
  • Its Cash & Equivalents was $647.0 million in Q3 2025, compared to $546.0 million in Q2 2025 and $489.0 million in Q1 2025.